Axial Therapeutics - A Kairos Ventures Portfolio Company

Company Summary

Axial Therapeutics™ is a clinical-stage biopharmaceutical company focused on the discovery and development of gut-restricted, small molecule therapeutics for central nervous system (CNS) disorders. The company is leveraging its expertise in the gut-brain axis and its unique drug development platform to advance novel therapies that have the potential to transform the treatment paradigm in neurodegenerative diseases.

Year Founded:  2016

Key Executives:
• David H. Donabedian, Co-founder, CEO and Director
• Sarkis Mazmanian, Co-founder and Director

Location:  Boston, MA

Website:  https://axialtx.com/

Company Status:  Private

Year Invested: 2016

Investment Status:  Current